Emergent BioSolutions Inc. (EBS): who owns it and who trades it
As of Nov 16, 2026, EBS insiders reported 13 open-market sales worth $986K and no purchases in the last 12 months, with 73% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ronald Richard (Director), with $263K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Emergent BioSolutions
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EBS
193 funds and institutions reported EBS shares worth $382M at the end of Q2 2026, about 88% of the company. The largest holder is BlackRock, Inc. with 9.1%.
Funds and institutions (13F) 88%Everyone else 12%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 4.72M | 9.14% | $39.5M | +9% |
| Dimensional Fund Advisors LP | 3.08M | 5.96% | $25.8M | +12% |
| State Street Corp | 2.93M | 5.68% | $24.6M | +3% |
| American Century Companies Inc | 2.77M | 5.37% | $23.2M | +14% |
| Vanguard Capital Management LLC | 2.20M | 4.26% | $18.4M | -3% |
| Lsv Asset Management | 1.70M | 3.29% | $14.2M | +89% |
| Acadian Asset Management LLC | 1.34M | 2.61% | $11.3M | -3% |
| Geode Capital Management, LLC | 1.34M | 2.59% | $11.2M | +5% |
| Charles Schwab Investment Management Inc | 1.20M | 2.33% | $10.1M | -20% |
| Sixth Street Partners Management Company, L.P. | 1.20M | 2.33% | $10.1M | – |
| Oak Hill Advisors LP | 1.11M | 2.16% | $9.3M | No change |
| Millennium Management LLC | 1.07M | 2.08% | $9M | +102% |
| Ancora Advisors LLC | 1.07M | 2.07% | $8.9M | +161% |
| AQR Capital Management LLC | 1.04M | 2.02% | $8.7M | +5% |
| Goldman Sachs Group Inc | 1.04M | 2.01% | $8.7M | +28% |
| Vanguard Portfolio Management LLC | 1.03M | 2.00% | $8.6M | -8% |
| D. E. Shaw & Co., Inc. | 900,108 | 1.74% | $7.5M | -10% |
| Russell Investments Group, Ltd. | 859,482 | 1.67% | $7.2M | +156% |
| Federated Hermes, Inc. | 831,125 | 1.61% | $7M | +82% |
| Prudential Financial Inc | 805,895 | 1.56% | $6.8M | +80% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EBS insiders reported $0 of open-market purchases and $986K of sales. 73% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Donald W DeGolyer | Director | Sale plan | 17,800 | $7.09 | $126K | Form 4 |
| Oct 1, 2026 | Paul Anthony Williams | Vice president | Sale plan | 3,000 | $6.53 | $19.6K | Form 4 |
| Jul 1, 2026 | Paul Anthony Williams | Vice president | Sale plan | 3,000 | $8.40 | $25.2K | Form 4 |
| May 1, 2026 | Sujata Tyagi Dayal | Director | Sale plan | 980 | $8.94 | $8.8K | Form 4 |
| May 1, 2026 | Sujata Tyagi Dayal | Director | Sale plan | 12,781 | $8.36 | $107K | Form 4 |
| May 1, 2026 | Donald W DeGolyer | Director | Sale plan | 954 | $8.96 | $8.5K | Form 4 |
| May 1, 2026 | Donald W DeGolyer | Director | Sale plan | 14,527 | $8.36 | $121K | Form 4 |
| May 1, 2026 | Kathryn C Zoon | Director | Sale plan | 1,057 | $8.97 | $9.5K | Form 4 |
| May 1, 2026 | Kathryn C Zoon | Director | Sale plan | 16,145 | $8.36 | $135K | Form 4 |
| Apr 30, 2026 | Keith Katkin | Director | Sale plan | 15,481 | $8.28 | $128K | Form 4 |
| Apr 1, 2026 | Paul Anthony Williams | Vice president | Sale plan | 4,000 | $8.44 | $33.8K | Form 4 |
| Dec 5, 2025 | Ronald Richard | Director | Sale | 14,884 | $11.90 | $177K | Form 4 |
| Dec 5, 2025 | Ronald Richard | Director | Sale | 7,100 | $12.11 | $86K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ronald Richard | Director | – | $263K | Dec 5, 2025 |
| Donald W DeGolyer | Director | – | $256K | Oct 7, 2026 |
| Kathryn C Zoon | Director | – | $144K | May 1, 2026 |
| Keith Katkin | Director | – | $128K | Apr 30, 2026 |
| Sujata Tyagi Dayal | Director | – | $116K | May 1, 2026 |
| Paul Anthony Williams | SVP, Products Business | – | $78.5K | Oct 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EBS short interest
High short interest. 19.6% of EBS shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 5%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.08M EBS shares were sold short, 19.6% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 1.00M shares, buying them all back would take about 10.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.08M | 19.61% | +4% | 1.00M | 10.1 |
| Oct 15, 2026 | 9.68M | 18.89% | +4% | 1.07M | 9.0 |
| Sep 30, 2026 | 9.29M | 18.13% | -5% | 1.12M | 8.3 |
| Sep 15, 2026 | 9.79M | 19.09% | -10% | 1.14M | 8.6 |
| Aug 31, 2026 | 10.84M | 21.15% | -7% | 1.19M | 9.2 |
| Aug 14, 2026 | 11.64M | 22.70% | +16% | 1.94M | 6.0 |
| Jul 31, 2026 | 10.03M | 19.56% | -3% | 568,258 | 17.6 |
| Jul 15, 2026 | 10.34M | 20.04% | +1% | 785,751 | 13.2 |
| Jun 30, 2026 | 10.27M | 19.90% | +5% | 1.28M | 8.0 |
| Jun 15, 2026 | 9.77M | 18.94% | +0% | 761,981 | 12.8 |
| May 29, 2026 | 9.76M | 18.92% | +2% | 848,439 | 11.5 |
| May 15, 2026 | 9.60M | 18.61% | -2% | 800,704 | 12.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded EBS
Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 1 sale of EBS. The latest was a sale by Steve Cohen on Dec 11, 2024, reported Jan 10, 2025.
Purchases 0Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Dec 11, 2024 | Steve Cohen (D-TN) | Sale | $1K–$15K | Self | Jan 10, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Emergent BioSolutions company events
Emergent BioSolutions filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026AnnouncementEmergent BioSolutions Inc. announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax ® (Anthrax Vaccine Adsorbed) to the U.S. Department of War. Filing
- Nov 2, 2026ResultsReleased financial results. Filing
- Oct 16, 2026LeadershipEmergent BioSolutions Inc. announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027. Filing
- Sep 14, 2026AnnouncementShared information with investors. Filing
- Sep 1, 2026AnnouncementEmergent BioSolutions Inc. received a contract modification of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as “AV7909”) valued… Filing
- Aug 5, 2026LeadershipIn connection with the actions described above, on August 5, 2026 the Company also announced that it will eliminate the role of Chief Medical Officer, Head of Research and Development. Filing
- Jun 29, 2026AgreementEmergent BioSolutions Inc., through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response, an agency of the U.S. Department of Health and Human Services, exercising… Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Apr 30, 2026VoteReported shareholder vote results. Filing
- Apr 17, 2026AgreementEmergent BioSolutions Inc. entered into a Credit Agreement by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent. Filing
- Mar 3, 2026LeadershipThe Board of Directors of Emergent BioSolutions Inc. appointed John D. Fowler, Jr. as a Class II director effective March 1, 2026, with his initial term expiring at the Company’s 2026 annual meeting of stockholders. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Dec 12, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Emergent BioSolutions financials
Famous investors that hold EBS
3 of the 50 well-known investors we track reported holding EBS in their latest 13F filing. The largest position is Israel Englander's, worth $12.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.88M | $12.4M | 0.0% | +75% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 724,147 | $4.8M | 0.0% | +6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 12,880 | $85K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named EBS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Oak Hill Advisors LP | 13G/A | 7.5% |
| Nov 16, 2026 | Oak Hill Advisors LP | 13G/A | 7.5% |
Questions about Emergent BioSolutions Inc. (EBS) stock
Who owns the most EBS stock?
The largest reported owner of Emergent BioSolutions Inc. (EBS) is BlackRock, Inc., with 9.1% of the company. In total, 193 funds and institutions reported holding EBS at the end of Q2 2026, together about 88% of the shares. See the largest owners.
Are EBS insiders buying or selling?
In the last 12 months, EBS insiders reported no open-market purchases and 13 sales worth $986K. The latest trade was on Oct 7, 2026. See every trade.
What is the short interest in EBS?
As of Oct 30, 2026, 10.08M EBS shares were sold short, 19.6% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 1.00M shares, buying them all back would take about 10.1 trading days (days to cover). See the history.
Have members of Congress traded EBS?
Yes. 1 member of Congress reported 0 purchases and 1 sale of EBS since Nov 17, 2024. The latest was reported on Jan 10, 2025. See the trades.
Which famous investors hold EBS?
3 of the 50 well-known investors we track reported EBS in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $12.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.